Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450联合安罗替尼治疗晚期三阴性乳腺癌的III期临床试验
CTR20201065Phase 3Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart in triple-negative breast cancer (TNBC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jun 2020; status: terminated.
02
Drugs
benmelstobart
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20201065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201065.